Would you consider the use of PARP inhibitors in patients with BARD 1 mutation and refractory pancreatic cancer?

Topics: Gastrointestinal Cancers • Medical Oncology • Liver and Pancreas Tumors

With extensive use of NGS testing, it is commonplace to identify mutations that have no validated therapeutic intervention, but strong biologic signal of potential benefit. What is your approach in such situations?

Answer from: Medical Oncologist at Community Practice

I will use it.In a disease like pancreatic adenocarcinoma, where treatment options are so limited, one has a much lower threshold to think out of the box. Of course there is no good (or any) data on the use of PARPi in this particular setting. However, with the manageable toxicity of the PARPi, I wo...

Comments

Medical Oncologist at University Medical Oncology
Thank you for your response.

Medical Oncologist at Jefferson Healthcare
Thank you. I am in the process of fighting an insu...

Related Questions